retatrutide 2025 trial results 💉𝗥𝗲𝘁𝗮𝘁𝗿𝘂𝘁𝗶𝗱𝗲'𝘀 𝗨𝗻𝗲𝘅𝗽𝗲𝗰𝘁𝗲𝗱 𝗦𝗶𝗱𝗲 𝗘𝗳𝗳𝗲𝗰𝘁: 𝗪𝗵𝗮𝘁 𝗬𝗼𝘂 𝗦𝗵𝗼𝘂𝗹𝗱 𝗞𝗻𝗼𝘄 𝗥𝗲𝘁𝗮𝘁𝗿𝘂𝘁𝗶𝗱𝗲: a new triple-agonist weight loss drug that is STILL IN CLINICAL TRIALS, is showing incredible results, with some Triple hormone receptor agonist retatrutide

As I discussed on Episode 80 of our podcast, The Future of GLP-1 Medications: Quick Pen and Dose Flexibility, our dilution approach has allowed patients to reduce their medication costs by a third or even a sixth of the traditional cost

Depending on how long treatment has been stopped, you may need to restart at a lower dose and increase gradually to reduce side effects

This study found that participants regained a significant portion of lost weight after discontinuing semaglutide: Rubino D et al., Discontinuation of GLP-1 Receptor Agonist Therapy and Weight Regain, Frontiers in Endocrinology , 2021

The FDA classifies BPC-157 as a Category 2 bulk drug substance meaning its not FDA-approved for human use and has been flagged as potentially presenting safety risks in unregulated compounding

They can control copper, a dangerous but important metal, making them useful for researching tissue healing, oxidative balance, and inflammation